Optimizing therapy for transplant-eligible patients with newly diagnosed multiple myeloma (Q38062036)

28 August 2017

1 reference

title

Optimizing therapy for transplant-eligible patients with newly diagnosed multiple myeloma (English)

1 reference

28 August 2017

Philippe Moreau

1

1 reference

28 August 2017

Sergio A Giralt

series ordinal

2

1 reference

28 August 2017

publication date

1 November 2012

1 reference

28 August 2017

1 reference

28 August 2017

volume

36 Suppl 1

1 reference

28 August 2017

page(s)

S13-8

1 reference

Review of 1027 patients with newly diagnosed multiple myeloma

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Recent major improvement in long-term survival of younger patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Improved survival in multiple myeloma and the impact of novel therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Improved survival among younger but not among older patients with Multiple Myeloma in the Netherlands, a population-based study since 1989.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

The immune microenvironment of myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Evolving role of novel agents for maintenance therapy in myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

How I treat multiple myeloma in younger patients

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Effects of Lenalidomide and Dexamethasone Treatment Duration on Survival in Patients With Relapsed or Refractory Multiple Myeloma Treated With Lenalidomide and Dexamethasone

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Clinical course of patients with relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Maintenance therapy in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

How much and how long: tyrosine kinase inhibitor therapy in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Therapeutic approaches for newly diagnosed multiple myeloma patients in the era of novel drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Interferon-alpha as maintenance therapy in patients with multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Maintenance therapy with thalidomide improves survival in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Lenalidomide and thalidomide: mechanisms of action--similarities and differences

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Lenalidomide after stem-cell transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Malignant neoplasms in long-term survivors of bone marrow transplantation. Late Effects Working Party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

The Chemotherapy of Plasma-Cell Myeloma and the Incidence of Acute Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Acute leukaemia and other secondary neoplasms in patients treated with conventional chemotherapy for multiple myeloma: a Finnish Leukaemia Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Myeloma and second primary cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised p

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Consolidation therapy with bortezomib/lenalidomide/ dexamethasone versus bortezomib/dexamethasone after a dexamethasone-based induction regimen in patients with multiple myeloma: a randomized phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

How to treat a newly diagnosed young patient with multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Thalidomide for treatment of multiple myeloma: 10 years later

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek myeloma study group

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Impact of response to thalidomide-, lenalidomide- or bortezomib- containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone (BLD).

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2812%2970004-8

7 January 2021

10.1016/S0145-2126(12)70004-8

Identifiers

DOI

1 reference

28 August 2017

1 reference